A review of the diagnosis and treatment of Ochratoxin A inhalational exposure associated with human illness and kidney disease including focal segmental glomerulosclerosis.
Janette H Hope, Bradley E Hope
Index: J. Environ. Public Health 2012 , 835059, (2012)
Full Text: HTML
Abstract
Ochratoxin A (OTA) exposure via ingestion and inhalation has been described in the literature to cause kidney disease in both animals and humans. This paper reviews Ochratoxin A and its relationship to human health and kidney disease with a focus on a possible association with focal segmental glomerulosclerosis (FSGS) in humans. Prevention and treatment strategies for OTA-induced illness are also discussed, including cholestyramine, a bile-acid-binding resin used as a sequestrant to reduce the enterohepatic recirculation of OTA.
Related Compounds
Related Articles:
2007-08-17
[J. Biol. Chem. 282 , 23841-53, (2007)]
Role of microRNA-29b in the ochratoxin A-induced enhanced collagen formation in human kidney cells.
2014-10-03
[Toxicology 324 , 116-22, (2014)]
Development of a stir bar sorptive extraction method for analysis of ochratoxin A in beer.
2014-01-01
[J. AOAC Int. 97(4) , 1092-6, (2014)]
2015-02-02
[Int. J. Food Microbiol. 194 , 71-7, (2015)]
2014-05-16
[Int. J. Food Microbiol. 178 , 113-9, (2014)]